Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine Biosciences (NBIX)
:NBIX
Holding NBIX?
Track your performance easily
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.95 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)968.04K
Market Cap
$14.50B
Enterprise Value$11.08B
Total Cash (Recent Filing)$307.35M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)38.4
Beta0.55
Next Earnings
Feb 11, 2025EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding101,246,910
10 Day Avg. Volume962,733
30 Day Avg. Volume968,036
Standard Deviation0.08
R-Squared0.04
Alpha0.00350
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.47
Price to Cash Flow (P/CF)23.00
P/FCF Ratio24.20
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda19.90
Forecast
1Y Price Target
$166.88Price Target Upside16.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Clinical SuccessCrinecerfont's Phase 3 results support broad application, indicating strong clinical success.
Market PotentialThe market for CAH is seen as underappreciated over the longer term, indicating significant growth potential for NBIX.
Product ApprovalThe FDA approved Crenessity for classic congenital adrenal hyperplasia for adult and pediatric patients, which was modestly earlier than expected.
Bears Say
Clinical TrialsRecent clinical trial struggles, specifically in epilepsy, make analysts interested in these assets, but unlikely to ascribe much value.
Launch ChallengesA slow launch of Crenessity is anticipated due to challenges such as limited broad commercial access and a complicated dosing regimen.
Market AcceptanceCrenessity's annual list price is significantly higher than market expectations, which could impact affordability and market acceptance.
---
Ownership Overview
1.04% Insiders
22.90% Mutual Funds
0.28% Other Institutional Investors
48.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine Biosciences’s price range in the past 12 months?
Neurocrine Biosciences lowest stock price was $110.95 and its highest was $157.98 in the past 12 months.
What is Neurocrine Biosciences’s market cap?
Neurocrine Biosciences’s market cap is $14.50B.
When is Neurocrine Biosciences’s upcoming earnings report date?
Neurocrine Biosciences’s upcoming earnings report date is Feb 11, 2025 which is in 20 days.
How were Neurocrine Biosciences’s earnings last quarter?
Neurocrine Biosciences released its earnings results on Oct 30, 2024. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.505 by -$0.265.
Is Neurocrine Biosciences overvalued?
According to Wall Street analysts Neurocrine Biosciences’s price is currently Undervalued.
Does Neurocrine Biosciences pay dividends?
Neurocrine Biosciences does not currently pay dividends.
What is Neurocrine Biosciences’s EPS estimate?
Neurocrine Biosciences’s EPS estimate is 1.61.
How many shares outstanding does Neurocrine Biosciences have?
Neurocrine Biosciences has 101,246,910 shares outstanding.
What happened to Neurocrine Biosciences’s price movement after its last earnings report?
Neurocrine Biosciences reported an EPS of $1.24 in its last earnings report, missing expectations of $1.505. Following the earnings report the stock price went up 7.006%.
Which hedge fund is a major shareholder of Neurocrine Biosciences?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$166.88 (16.49% Upside)
$166.88 (16.49% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 66.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.47%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
24.11%
Trailing 12-Months
Company Description
Neurocrine Biosciences
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong sales figures for INGREZZA and significant progress in pipeline development. While some challenges were noted, particularly in terms of competition and program discontinuations, the strategic initiatives like the share repurchase plan and sales force expansion reflect confidence in future growth.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$166.88
▲(16.49% Upside)
Technical Analysis
SAGE Therapeutics
―
ACADIA Pharmaceuticals
―
Alkermes
―
Vertex Pharmaceuticals
―
Incyte
―
Xencor
―
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
22/27 ratings generated profit
1 Year Average Return
+12.64%
assigned a buy rating 10 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 81.48% of your transactions generating a profit, with an average return of +12.64% per trade.
---